Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX15 | P16050 | 2/20 | 0.70 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.70 |
| ▸ | TSHR | P16473 | 2/20 | 0.60 |
| ▸ | MEN1 | O00255 | 2/20 | 0.60 |
| ▸ | GJA1 | P17302 | 1/20 | 0.60 |
| ▸ | GJB2 | P29033 | 1/20 | 0.60 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.60 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | HPSE | Q9Y251 | 1/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 1/20 | 0.54 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.53 |
| ▸ | LRAT | O95237 | 1/20 | 0.51 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12899390 | 0.94 | ALOX15 (0.79) | ALOX15KDM4ETSHRMEN1GJA1 | |
| SCHEMBL29885022 | 0.88 | LMNA (0.70) | ALOX15KDM4ETSHRMEN1GJA1 | |
| SCHEMBL418521 | 0.87 | ALOX15 (0.90) | ALOX15KDM4ETSHRMEN1GJA1 | |
| SCHEMBL14922823 | 0.87 | ALOX15 (0.90) | ALOX15KDM4ETSHRMEN1GJA1 | |
| Bekanamycin SCHEMBL23879718 | 0.83 | ALOX15 (1.00) | ALOX15KDM4ETSHRMEN1GJA1 | |
| Bekanamycin SCHEMBL17265214 | 0.83 | ALOX15 (1.00) | ALOX15KDM4ETSHRMEN1GJA1 | |
| Bekanamycin SCHEMBL19917387 | 0.83 | ALOX15 (1.00) | ALOX15KDM4ETSHRMEN1GJA1 | |
| Bekanamycin SCHEMBL9250504 | 0.83 | ALOX15 (1.00) | ALOX15KDM4ETSHRMEN1GJA1 | |
| Bekanamycin SCHEMBL16174041 | 0.83 | ALOX15 (1.00) | ALOX15KDM4ETSHRMEN1GJA1 | |
| Bekanamycin SCHEMBL12535725 | 0.83 | ALOX15 (1.00) | ALOX15KDM4ETSHRMEN1GJA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9469863-B2 | Aminoglycoside antibiotics, process for producing the same, and pharmaceutical use thereof | MEIJI SEIKA KAISHA, LTD. (JP) | 2016-10-18 | — | — | US | disclosed |
| US-9469863-B2 | Aminoglycoside antibiotics, process for producing the same, and pharmaceutical use thereof | MEIJI SEIKA KAISHA, LTD. (JP) | 2016-10-18 | — | — | US | disclosed |
| EP-2226388-B1 | NOVEL AMINOGLYCOSIDE ANTIBIOTIC, METHOD FOR PRODUCING THE SAME, AND PHARMACEUTICAL USE OF THE SAME | MEIJI SEIKA PHARMA CO LTD (JP) | 2016-02-17 | — | — | EP | disclosed |
| US-20110034405-A1 | NOVEL AMINOGLYCOSIDE ANTIBIOTICS, PROCESS FOR PRODUCING THE SAME, AND PHARMACEUTICAL USE THEREOF | MEIJI SEIKA KAISHA, LTD. | 2011-02-10 | — | — | US | disclosed |
| EP-2226388-A1 | NOVEL AMINOGLYCOSIDE ANTIBIOTIC, METHOD FOR PRODUCING THE SAME, AND PHARMACEUTICAL USE OF THE SAME | Meiji Seika Kaisha Ltd. (JP) | 2010-09-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110034405-A1 | NOVEL AMINOGLYCOSIDE ANTIBIOTICS, PROCESS FOR PRODUCING THE SAME, AND PHARMACEUTICAL USE THEREOF | AARS1, AASDHPPT, DHPS | ALOX15 3336/4885KDM4E 2017/4885TSHR 3729/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.